ADAR1 Capital Management’s Silence Therapeutics SLN Stock Holding History

ADAR1 Capital Management’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.72M	Buy	338,373 +166,216	+97%	+$1.17M	0.17%	115
2026 Q1	$907K	Buy	172,157 +148,514	+628%	+$818K	0.05%	168
2025 Q4	$144K	Buy	23,643 +5,000	+27%	+$32K	0.01%	238
2025 Q3	$96.8K	Hold	18,643	–	–	0.01%	202
2025 Q2	$108K	Hold	18,643	–	–	0.02%	172
2025 Q1	$52.6K	Buy	18,643 +643	+4%	+$3.14K	0.01%	180
2024 Q4	$124K	Sell	18,000 -22,290	-55%	-$288K	0.02%	174
2024 Q3	$732K	Hold	40,290	–	–	0.12%	96
2024 Q2	$766K	Buy	40,290 +200	+0.5%	+$4.25K	0.14%	78
2024 Q1	$866K	Buy	40,090 +39,900	+21,000%	+$867K	0.2%	63
2023 Q4	$3.3K	Buy	+190	New	+$2.13K	﹤0.01%	153

Other funds holding SLN

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

ADAR1 Capital Management's SLN Position: Q2 2026 in Review

ADAR1 Capital Management increased its Silence Therapeutics (SLN) stake by 97% in Q2 2026, buying an estimated $1.17M and bringing the position to 338,373 shares worth $3.72M. The position accounts for 0.17% of the portfolio, ranked #115.

ADAR1 Capital Management first reported a position in SLN in Q4 2023 and has held it in 11 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

ADAR1 Capital Management held 338,373 shares of Silence Therapeutics worth $3.72M as of Q2 2026.
ADAR1 Capital Management bought 166,216 Silence Therapeutics shares in Q2 2026, an estimated $1.17M.
Silence Therapeutics made up 0.17% of ADAR1 Capital Management's portfolio in Q2 2026, its #115 holding.
ADAR1 Capital Management first reported a position in Silence Therapeutics in Q4 2023 and has held it in 11 quarters since.
72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.